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Abstract
Introduction The addition of statins to standard care in heart failure (HF) patients remains controversial in clinical practice.
Large-scale clinical trials failed to show mortality beneﬁts, but uncertainty persists in real-world settings.
Objective We evaluated whether the prescription of statins at hospital discharge is associated with a reduction in all-cause
mortality at up to 1 year of follow-up in HF patients.
Methods We analyzed data from Epidémiologie et Pronostic de l’Insuﬃsance Cardiaque Aiguë en Lorraine (EPICAL2)
cohort study of 2254 hospitalized acute HF patients who were admitted to 21 hospitals located in northeast France for acute 
HF between October 2011 and October 2012 and who received statins at discharge compared with patients who did not. 
We used propensity score matching and instrumental variable analyses to estimate the treatment eﬀects of statins, and a 
multivariable Cox proportional-hazards model to examine survival with statin use, adjusting for patient demographics, HF 
characteristics, medical history, comorbidities, drug treatment and other known potential confounders. We plotted Kaplan–
Meier survivor curves, and used log-rank test to determine the equality of survivor functions.
Results We included 2032 patients in this investigation: 919 (45%) in the statin-treated group and 1113 (55%) in the control 
group. The estimated average statin-treatment eﬀects for all-cause mortality in HF failed to demonstrate a signiﬁcant eﬀect 
on mortality [Z = − 1.73, 95% conﬁdence interval (CI) − 0.11 to 0.007, p value = 0.083, and Z = − 0.95, 95% CI − 1.34
to 0.46, p value = 0.34] for propensity score matching and instrumental variable analyses, respectively. Moreover, the Cox
proportional-hazards model showed that statin prescription was not signiﬁcantly associated with the rate of death (hazard 
ratio = 0.85, 95% CI 0.66–1.11, p value = 0.26), adjusted for all confounders.
Conclusion In patients with HF (and reduced or preserved ejection fraction), the prescription of statins did not appear to be
associated with better survival after 1 year of follow-up in the EPICAL2 cohort. We cannot exclude that a subpopulation 
of HF patients may have some beneﬁts compared with the whole HF population or that there might be a lack of power to 
show such eﬀect.
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Key Points 
There is moderate evidence from large-scale clinical tri-
als and meta-analyses that statins fail to reduce mortal-
ity in heart failure (HF) patients, including ischemic 
cardiomyopathy.
Scarce real-world data exist in the literature to encourage 
or discourage the use of statins in clinical practice.
Our Epidémiologie et Pronostic de l’Insuﬃsance Car-
diaque Aiguë en Lorraine (EPICAL2) observational 
cohort study failed to show mortality beneﬁts for statin 
use post-discharge, in line with large-scale clinical trials, 
but we do not exclude potential beneﬁts in a speciﬁc HF 
subpopulation.
1 Introduction
Despite progress and current advances in heart failure (HF) 
therapies, 50% of patients die within 5 years of initial diag-
nosis [1]. Therefore, there is a growing need to prevent 
all-cause mortality and to optimize therapeutic strategies. 
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, or simply “statins,” in addition to 
drugs recommended in HF [angiotensin-converting enzyme 
inhibitors (ACE-i), beta-blockers (BBs), and mineralocor-
ticoid inhibitors], have been hypothesized to further reduce 
mortality compared with usual care. However, HF patients 
were systematically excluded from most clinical trials with 
statins, leaving us with limited data and moderate evidence 
[2]. Unlike large-scale clinical trials [3, 4], some observa-
tional studies reported that statins were eﬀective in all-cause 
mortality reduction [5, 6], raising discrepancies and debates. 
Therefore, it appeared important to ﬁnd out if a further anal-
ysis of a well-conducted observational study could add new 
evidence to the current literature. In our analysis, we used 
data from the Epidémiologie et Pronostic de l’Insuﬃsance 
Cardiaque Aiguë en Lorraine (EPICAL2) cohort study of 
2254 hospitalized acute HF patients, recruited between 
October 2011 and October 2012 from 21 hospitals located 
in the Lorraine region of northeast France, to examine if the 
prescription of statins at hospital discharge for an HF-related 
hospitalization was associated with better 1-year survival.
2  Methods
2.1  Participants
The methods of recruitment and patient characteristics 
have been already published elsewhere [7, 8]. In brief, this 
cohort (EPICAL2, NCT02880358) included 2254 patients 
who were hospitalized in the Lorraine region of northeast 
France (2,350,000 inhabitants, according to the 2012 cen-
sus) for acute HF between October 2011 and October 2012 
and followed for 1 year after hospital discharge. In our 
present analysis, we selected patients who were exposed to 
statin treatment after hospital discharge. The type of statin 
could be any of the following: rosuvastatin, pravastatin, 
atorvastatin, simvastatin, lovastatin, ﬂuvastatin, cerivasta-
tin and pitavastatin. Besides sociodemographic and clini-
cal data, treatment data were collected by standardized 
forms at inclusion, during the index hospitalization and at 
discharge [7, 8]. The baseline characteristics of included 
patients are reported in Table 1. In the present analysis, 
we excluded patients who died before discharge from the 
index hospitalization, those who had unknown prescription 
status for statins, and those who were lost to follow-up or 
had an unknown vital status after 1 year of follow-up from 
the index hospitalization (Fig. 1). Of note, the EPICAL2 
cohort study was conducted according to the principles 
of the Declaration of Helsinki and approved by national 
ethics committees (Comité Consultatif sur le Traitement 
de l’Information en Matière de Recherche, Commission 
Nationale de l’Informatique et des Libertés). All eligible 
patients were informed about the study protocol and were 
free to refuse to be included in the cohort.
2.2  Variables Selection
Independent variables used for the present analysis were 
those known to inﬂuence mortality and those that might 
be related to initiating or maintaining statin treatment. 
These variables were age, gender, hypertension, body mass 
index (BMI), left ventricular ejection fraction (LVEF), 
New York Heart Association (NYHA) class III or IV, 
increased brain natriuretic peptide (BNP) or N-terminal 
prohormone of brain natriuretic peptide (NT-proBNP), 
hemoglobin level, alcohol abuse, smoking status, previous 
history of HF, hospital stay duration, angina, history of 
stroke/transient ischemic attack (TIA), arrhythmias, dys-
lipidemia, history of acute coronary syndrome, chronic 
obstructive pulmonary disease (COPD)/asthma, diabetes, 
chronic kidney disease, malignant hemopathies or any can-
cer, and usual treatment with BBs, ACE-i, and spironol-
actone. We included the prescription of BBs, ACE-i, and 
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Table 1  Characteristics of included HF patients according to treatment with statins
ACE-i angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, BBs beta-blockers, BMI body mass index, BNP brain natriu-
retic peptide, COPD chronic obstructive pulmonary disease, HF heart failure, LVEF left ventricular ejection fraction, NT-proBNP N-terminal 
prohormone of brain natriuretic peptide, NYHA New York Heart Association classiﬁcation, SD standard deviation, TIA transient ischemic attack
a Values are n (%) unless otherwise stated
b Deleted in models for collinearity
c BNP > 400 pg/mL or NT-proBNP > 450 pg/mL in patients < 50 years; NT-proBNP > 900 pg/mL in patients 50–75 years; NT-proBNP > 
1800 pg/mL in patients > 75 years [7, 9]
d Variables with missing values (>19%)
Selected variables Statins (N = 919) n (%)a No statins (N = 
1113) n (%)a
p value Standardized diﬀerences for 
unmatched sample (%)
Standardized diﬀer-
ences for matched 
sample
Demographic characteristics
 Mean (SD) age (years) 74.92 (11.06) 79.15 (11.57) < 0.001 − 30.8 1.8
  ≤ 65 186 (20.24%) 155 (13.93%)
  ≥ 66–≤ 80 400 (43.53%) 329 (29.56%)
  > 80 333 (36.24%) 629 (56.51%)
 Female 383 (41.68%) 655 (58.85%) < 0.001 − 35.9 − 0.5
Clinical characteristics
 Hypertension 716 (77.91%) 841 (75.56%) 0.213 2.3 − 3.1
 Mean (SD) BMI (kg/m2)d 28.91 (6.4) 28.17 (6.7) 0.0247 16.9 − 3.0
  < 25 (underweight or normal) 207 (27.20%) 310 (35.59%)
  ≥ 25–< 30 (overweight) 255 (33.51%) 264 (30.31%)
  ≥ 30 (obese) 299 (39.29%) 297 (34.10%)
 LVEF (%)d 0.039 11.7 − 8.5
  < 40 317 (43.66%) 311 (39.82%)
  ≥ 40 409 (56.34%) 470 (60.18%)
 NYHA class III or IV (severe HF) 734 (79.96%) 927 (83.59%) 0.034 − 17.6 − 3.9
 Increased BNP or NT-proBNPc 580 (63.11%) 680 (61.10%) 0.351 2.4 7.1
 Hemoglobin < 10 g/dL 97 (10.90%) 121 (11.27%) 0.796 − 6.7 − 2.7
Medical history
 Alcohol abuse 80 (8.71%) 113 (10.15%) 0.268 − 3.7 4.7
 Smoking 396 (43.09%) 340 (30.55%) < 0.001 29.3 2.9
 History of  HFb 507 (55.17%) 641 (57.59%) 0.273 b
 Mean (SD) hospital stay duration (days) 11.89 (10.83) 12.31 (10.86) 0.3830 − 3.6 5.0
 Angina 139 (15.13%) 95 (8.54%) < 0.001 16.2 − 2.7
 History of stroke/TIA 131 (14.25%) 129 (11.59%) 0.074 5.0 3.3
 Arrhythmias 450 (48.97%) 700 (62.89%) < 0.001 − 34.2 − 0.3
 Dyslipidemia 533 (58%) 299 (26.86%) < 0.001 61.2 − 5.9
HF etiology
 Acute coronary syndrome 204 (22.20%) 61 (5.48%) < 0.001 50.3 8.3
Comorbidities
 COPD/asthma 216 (23.50%) 241(21.65%) 0.320 6.5 5.0
 Diabetes 378 (41.13%) 355 (31.90%) < 0.001 18.3 − 6.0
 Chronic kidney disease 210 (22.85%) 268 (24.08%) 0.516 − 9.3 − 0.4
 Leukemia or any cancer 145 (15.78%) 188 (16.89%) 0.500 − 7.0 − 2.0
 Atrial ﬁbrillation 266 (28.94%) 515 (46.27%) < 0.001
Treatments
 BBs 552 (60.07%) 531 (47.71%) < 0.001 19.0 3.9
 ACE-i 563 (61.26%) 535 (48.07%) < 0.001
 ARB 151 (16.43%) 204 (18.33%) 0.262
 Spironolactone 86 (9.36%) 145 (13.03%) 0.009
 Amiodarone 225 (24.48%) 267 (23.99%) 0.796
 Previous exposure to statins 675 (77.68%) 83 (8.01%) < 0.001
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spironolactone among the selected variables because they 
are known to be associated with a better prognosis [7, 9]. 
We deﬁned the variable “increased BNP or NT-proBNP 
(pg/mL)” based on the literature [8, 10] at the time of 
the EPICAL2 recruitment phase: BNP > 400 pg/mL or 
NT-proBNP > 450 pg/mL in patients < 50 years, NT-
proBNP > 900 pg/mL in patients 50–75 years, and NT-
proBNP > 1800 pg/mL in patients > 75 years. For statisti-
cal analysis, we dichotomized some variables: hemoglobin 
level (< 10 g/dL), hospital stay duration (≥ 9 days), and 
hypertensive cardiomyopathy (yes or no). Variables were 
prospectively deﬁned in the EPICAL2 study. For example, 
comorbidities were determined using International Classi-
ﬁcation of Diseases 10th Revision (ICD-10) codes in addi-
tion to the Charlson Comorbidity Index for data analyses.
2.3  Statistical Analysis
For bivariate analyses, we used Pearson Chi square for 
dichotomous categorical variables and two-sample unpaired 
t test for continuous variables. We assumed that the data 
were normally distributed and used the Shapiro–Wilk and 
the Shapiro–Francia test statistics to verify normality in 
addition to plotting histograms. We reported the baseline 
Fig. 1  Flow chart for heart fail-
ure patients from Epidémiologie 
et Pronostic de l’Insuﬃsance 
Cardiaque Aiguë en Lor-
raine (EPICAL2) to evaluate 
statin eﬀectiveness on all-cause 
mortality
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characteristics between compared groups. In our study, 
patients with missing data were deleted from the analyses. 
We considered a two-sided alpha value of < 5% as statisti-
cally signiﬁcant. We analyzed data with STATA version 14.2 
(StataCorp LP, Texas).
2.3.1  Propensity Score Analysis
The propensity score has been deﬁned as the conditional 
probability of assignment to a particular treatment (here, 
statins) given a vector of observed covariates [11]. Propen-
sity scores allow reducing bias and increasing precision 
of treatment eﬀects estimation [12, 13]. We calculated the 
propensity scores (i.e., the probability of being treated with 
statins) using multivariable logistic regression, without 
including the outcome (all-cause mortality) and performed 
balance assessment tests to compare the distribution of 
covariates between treated and control patients [14]. We 
used one-to-many matching with replacement as it produced 
better balance between treated and control groups than one-
to-one matching without replacement. Then we estimated 
treatment eﬀects and their standard errors using propensity 
score matching methods within a caliper distance of 0.2 [15, 
16]. On the propensity score step calculation, we included 
variables associated with both the outcome and the treatment 
assignment. The selected independent variables were age, 
gender, hypertension, BMI, LVEF, NYHA class III or IV, 
increased BNP or NT-proBNP, hemoglobin level, alcohol 
abuse, smoking status, hospital stay duration, angina, history 
of stroke/TIA, arrhythmias, dyslipidemia, history of acute 
coronary syndrome, COPD/asthma, diabetes, chronic kidney 
disease, malignant hemopathies or any cancer, atrial ﬁbril-
lation, and prescription of beta-blockers, angiotensin-con-
verting enzyme inhibitors and spironolactone. We included 
all aforementioned variables in our models except the 
variable “history of HF” because of collinearity. We tested 
beforehand the overlap of the propensity score between the 
treated and control groups. Thereafter, we checked the bal-
ance of the mean of the propensity score throughout the 
blocks, where eight blocks were created in the propensity 
scores calculation. We intended to re-specify the selected 
covariates (by categorizing or dichotomizing, for instance) 
if imbalance appeared. To avoid imbalance between groups, 
we deleted the “atrial ﬁbrillation” variable from propensity 
score calculation as it caused an unsatisﬁed balance. This 
is perhaps attributed to the potentially perfect prediction by 
the variable “arrhythmia”. Nonetheless, we re-entered this 
variable in the propensity score model in sensitivity analy-
ses. For the same reason of achieving balance of covariates, 
we categorized the variable “age” into three classes (≤ 65, 
66–80, and > 80) and dichotomized the variable “hospital 
stay duration (days)” to < 9 days or ≥ 9 days. Before esti-
mating treatment eﬀects, we further assessed the balance 
or the distribution of covariates across treated and control 
groups by measuring the standardized diﬀerences between 
compared groups. We measured the average eﬀect of the 
treatment on the patients who received the treatment [i.e., 
the average treatment eﬀects on the treated group (ATT)]. 
In addition to ATT estimation, we reported the respective 
standard errors, coeﬃcients, conﬁdence intervals (CIs) and 
p values.
2.3.2  Instrumental Variable Analysis
Propensity scores balance for measured covariates but not 
necessarily for unmeasured covariates [16]. Conversely, the 
instrumental variables approach takes into account unmeas-
ured variables that are associated with the treatment but not 
directly with the outcome. As an instrumental variable, we 
used the prevalence of statin prescription at discharge in our 
cohort in participating hospitals, denoted F. The endogenous 
explanatory variable was the statin treatment, denoted X. 
The outcome was all-cause mortality, denoted Y. We, there-
fore, tested the following hypothesis:
• F is correlated with X, conditional on other covariates.
• F has no direct eﬀect on Y, but only via X.
Using a two-stage least squares method, we regressed the 
instrumental variable, the prevalence of statin treatment in 
the participating hospitals (dichotomized as above or below 
the median of 47%), on other covariates previously used for 
the propensity score analysis. We veriﬁed the null hypoth-
eses that our instrument is weak and/or that the variables are 
exogenous (test of endogeneity).
2.3.3  Kaplan–Meier Survival Curves and Cox 
Proportional-Hazards Model
For survival analyses, we declared our data to be time to 
event. Our event of interest was all-cause mortality, while 
the time of follow-up was set up at 1 year and censored after-
wards. We plotted Kaplan–Meier survival curves by statin 
treatment, unadjusted and adjusted, for the same covariates 
used in the propensity score analysis.
We used a log-rank test to determine the equality of sur-
vivor functions, used a stratiﬁed log-rank test (on propen-
sity scores), and the stratiﬁed Wilcoxon (Breslow) test to 
compare survival curves. To illustrate the increased rate of 
having an event, we regressed all-cause mortality (the out-
come) on independent variables—previously adjusted for 
in Kaplan–Meier survivor curves—in a multivariable Cox 
proportional-hazards model with Breslow methods for ties. 
We veriﬁed the proportional-hazards assumption by a global 
test for all covariates included in the model and based on 
Schoenfeld residuals for all covariates individually.
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2.3.4  Subgroup Analyses
As subgroup analysis was based on the type of HF, we 
conducted a multiple logistic regression to verify if there 
were any diﬀerences in the eﬀect of statins in such sub-
populations. The independent variables were age, gender, 
hypertension, BMI, NYHA class III or IV, increased BNP 
or NT-proBNP, hemoglobin level, alcohol abuse, smoking 
status, hospital stay duration, angina, history of stroke/TIA, 
arrhythmias, dyslipidemia, history of acute coronary syn-
drome, COPD/asthma, diabetes, chronic kidney disease, 
malignant hemopathies or any cancer, and usual treatment 
with beta-blockers, angiotensin-converting enzyme inhibi-
tors, or spironolactone. As classiﬁed in many large-scale ran-
domized clinical trials [4, 17], we deﬁned the patients who 
had an ejection fraction less than 40% as HF with reduced 
ejection fraction (HFrEF) and those with an ejection frac-
tion equal or more than 40% as HF with preserved ejection 
fraction (HFpEF).
3  Results
3.1  Participants’ Sociodemographic, Medical 
History, and Clinical Characteristics
As shown in Fig. 1, we analyzed 2032 subjects out of the 
2254 included in the cohort. Those treated with statins 
[treated group (45%)] were compared with those not treated 
with statins [control group (55%)]. The number of deaths in 
our sample was 539; 195 (21%) occurred in the treated group 
versus 344 (31%) in the control group.
Table 1 shows comparisons of demographic, clinical and 
therapeutic characteristics between the group treated with 
statins and the control group. Statin-group patients were 
younger and more often male and smokers; they had less 
severe HF, but more often had angina or a history of acute 
coronary syndrome, dyslipidemia, or diabetes. However, 
they less often had arrhythmia or atrial ﬁbrillation related 
events. In addition, statin-group patients were more often 
treated with BBs and ACE-i, and were more exposed to 
statins before hospitalization, but were less often treated 
with spironolactone. The test of normality for the selected 
variables, including the Shapiro–Wilk and Shapiro–Francia 
statistics, conﬁrmed our hypothesis of normality assumption.
3.2  Propensity Score Matching
Once the propensity scores were calculated, we assessed 
the overlap of the propensity scores between the treated 
and control groups that appeared subjectively satisfying 
(Fig. 2). After that, we matched the treated group to the 
control group and estimated the ATT. The matched sample 
had 1197 patients (60%), excluding 835 observations with 
missing values in the following covariates: LVEF, BMI, 
hospital stay duration, and hemoglobin level. We describe 
the characteristics of unmatched compared with matched 
patients in Table 2.
After propensity score matching, t tests showed that the 
distributions of covariates were balanced between treated 
and control groups, except for the variable hypertension, 
Fig. 2  Distribution and degree 
of overlap of the propensity 
score between statin-treated and 
control groups in the included 
HF patients. HF heart failure
0 .2 .4 .6 .8 1
Propensity Score
Untreated Treated
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Table 2  Characteristics of matched and unmatched patients according to propensity scores
ACE-i angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, BBs beta-blockers, BMI body mass index, BNP brain natriu-
retic peptide, COPD chronic obstructive pulmonary disease, HF heart failure, LVEF left ventricular ejection fraction, NT-proBNP N-terminal 
prohormone of brain natriuretic peptide, NYHA New York Heart Association classiﬁcation, SD standard deviation, TIA transient ischemic attack
a BNP >  400  pg/mL or NT-proBNP >  450  pg/mL in patients <  50  years; NT-proBNP >  900  pg/mL in patients 50–75  years; NT-proBNP 
> 1800 pg/mL in patients > 75 years [7, 9]
b Deleted in models for collinearity
Selected variables Matched (n = 1197) Unmatched (n = 835)
Demographic characteristics
 Age (years) 75.43 (SD 12.11) 79.83 (SD 10.10)
  < 65 (%) 20.80 11.02
  > 66–≤ 80 (%) 38.43 32.22
  > 80 (%) 40.77 56.77
 Female (%) 41.68 58.85
Clinical characteristics
 Hypertension (%) 77.19 75.81
 BMI (kg/m2) 28.27 29.20
  < 25 (underweight or normal) (%) 33.42 26.90
  > 25–< 30 (overweight) (%) 31.08 33.79
  > 30 (obese) (%) 35.51 39.31
 LVEF (%)
  < 40 42.02 40.32
  ≥ 40 57.98 59.68
 NYHA class III or IV (severe HF) (%) 80.87 83.49
 Increased BNP or NT-proBNP (pg/mL) (%)a 64.83 57.96
 Hemoglobin < 10 g/dL (%) 10.94 11.34
Medical history
 Alcohol abuse (%) 10.11 8.62
 Smoking (%) 41.60 28.50
 Previous history of HF (%)b 55.14 58.44
 Hospital stay duration (days) 12.48 11.61
 Previous angina (%) 11.19 11.98
 Previous stroke/TIA (%) 11.78 14.25
 Previous or precipitating arrhythmias (%) 54.55 59.52
 Dyslipidemia (%) 43.94 36.65
HF etiology
 Acute coronary syndrome (%) 16.46 8.14
Comorbidities
 COPD/asthma (%) 22.31 22.75
 Diabetes (%) 35.25 37.25
 Chronic renal failure (%) 23.64 23.35
 Leukemia or any cancer (%) 16.12 16.77
 Atrial  ﬁbrillationb (%) 36.76 40.84
Treatments
 BBs (%) 57.06 47.90
 ACE-i (%) 58.73 47.31
 ARB (%) 17.63 17.25
 Spironolactone (%) 12.87 9.22
 Amiodarone (%) 24.39 23.95
 Previous exposure to statins (%) 41.62 37.23
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which showed imbalance in one block. In addition, the lack 
of diﬀerence between the statin and control groups was con-
ﬁrmed by the standardized diﬀerences (18.2% for unmatched 
sample versus 5.3% for matched sample). In the matching 
step, the number of matches per observation that had the 
best distribution of covariates among compared groups was 
three (maximum, four), and the caliper used was 0.2 times 
the standard deviation of the logit of the propensity scores. 
As a result, the estimated satin-treatment eﬀects (ATT) for 
all-cause mortality in HF showed no evidence of signiﬁcant 
reduction [coeﬃcient = − 0.055, AI robust standard error 
= 0.032; Z = − 1.73 (95% CI − 0.11 to 0.007); p value = 
0.083]. The re-entry of the variable “atrial ﬁbrillation” into 
the propensity score model caused unsatisﬁed balance in 
one block, but the estimated ATT were still insigniﬁcant 
[coeﬃcient = − 0.056, AI robust standard error = 0.029; Z 
= − 1.89 (95% CI − 0.11 to 0.002); p value = 0.058].
3.3  Instrumental Variable Analysis
Our instrumental variable, designated as the prevalence of 
statin prescription (denoted F) in participating hospitals, was 
associated with the treatment (denoted X) conditional on 
other covariates (p value = 0.019). In addition, F showed 
no direct association with the outcome, all-cause mortality 
(denoted Y). The test of endogeneity [Durbin (score) and 
Wu–Hausman] failed to reject our null hypothesis that the 
variables were exogenous (p value = 0.3). With the two-
stage least squares treatment estimation, the instrumental 
variable regression did not show a signiﬁcant decrease in 
death in the statin group versus the control group [coeﬃcient 
= − 0.43, standard error = 0.46; Z = − 0.95 (95% CI − 1.34 
to 0.46); p value = 0.34].
3.4  Kaplan–Meier Curves and Cox 
Proportional-Hazards Model
As mentioned before, the number of deaths in our study 
was 539; 195 (21%) occurred in the treated group versus 
344 (31%) in the control group. Unadjusted Kaplan–Meier 
survivor curves (Fig. 3) and the log-rank test showed sig-
niﬁcant results (p value < 0.001). However, the adjusted 
Kaplan–Meier survivor curves and the stratiﬁed log-rank test 
failed to show a signiﬁcant diﬀerence between the statin and 
control groups (p value = 0.317) (Fig. 4). We had similar 
results when we used a stratiﬁed log-rank test on propensity 
scores (p value = 1.00). Moreover, the multivariable Cox 
proportional-hazards model showed that statin use was not 
signiﬁcantly associated with the rate of death [hazard ratio 
(HR) = 0.85 (95% CI 0.66–1.11), p value = 0.26, and HR = 
0.86 (95% CI 0.66–1.13), p value = 0.3] when adjusted for 
the aforementioned independent variables or the propensity 
scores, respectively (see Table 3). The test of proportional-
hazard assumption was globally satisﬁed (p value = 0.21), 
but it appeared that the variable “hospital stay duration” was 
not, when checked individually. Consequently, we re-ran 
the Cox model without this variable, but the output stayed 
almost similar for statin treatment (p value = 0.20) and the 
Fig. 3  One-year survival in 
statin and control groups (unad-
justed Kaplan–Meier survivor 
curves)
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Fig. 4  One-year survival in sta-
tin and control groups (adjusted 
Kaplan–Meier survivor curves)
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Table 3  Hazard ratios for the independent variable (statins) and the explanatory variables
BMI body mass index, BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, HF heart failure, NT-proBNP N-terminal 
prohormone of brain natriuretic peptide, NYHA New York Heart Association classiﬁcation, TIA transient ischemic attack
a BNP >  400  pg/mL or NT-proBNP >  450  pg/mL in patients <  50  years; NT-proBNP >  900  pg/mL in patients 50–75  years; NT-proBNP 
> 1800 pg/mL in patients > 75 years [7, 9]
Variable name Hazard ratio Standard error Z p > [Z] 95% 
conﬁdence 
interval
Statins 0.85 0.11 − 1.13 0.260 0.66–1.11
Age 1.48 0.14 3.96 0.000 1.22–1.81
Female 0.85 0.11 − 1.17 0.242 0.64–1.11
Hypertensive cardiomyopathy (yes or no) 0.75 0.11 − 1.83 0.067 0.56–1.01
BMI 0.74 0.05 − 3.69 0.000 0.63–0.87
Ejection fraction (≥ 40) 1.24 0.16 1.64 0.100 0.95–1.61
NYHA (III or IV) 1.09 0.17 0.56 0.574 0.79–1.50
Increased  BNPa 1.32 0.17 2.10 0.036 1.01–1.72
Hemoglobin (< 10 g/dL) 1.15 0.20 0.82 0.411 0.81–1.64
Alcohol abuse 0.80 0.19 − 0.89 0.371 0.50–1.29
Smoking 0.88 0.13 − 0.77 0.443 0.65–1.19
Hospitalization duration (≥ 9 days) 1.66 0.21 3.98 0.000 1.29–2.14
Angina 1.12 0.21 0.60 0.54 0.77–1.62
Stroke/TIA 1.35 0.22 1.79 0.073 0.97–1.88
Arrhythmia 1.24 0.16 1.63 0.103 0.95–1.61
Dyslipidemia 0.81 0.10 − 1.57 0.116 0.62–1.05
HF with acute coronary syndrome 0.78 0.15 1.22 0.221 0.53–1.15
COPD 1.17 0.18 1.04 0.299 0.86–1.58
Diabetes 1.27 0.17 1.80 0.071 0.97–1.66
Renal failure 1.53 0.21 3.12 0.002 1.17–2.00
Cancer 1.51 0.22 2.81 0.005 1.13–2.02
Beta-blockers 0.78 0.09 − 1.88 0.060 0.61–1.00
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global test of proportional-hazard assumption was satisﬁed 
again (p value = 0.69).
3.5  Subgroup Analyses
There were no diﬀerences in the eﬀects of statins on HFrEF 
and HFpEF [odds ratio (OR) = 0.66 (95% CI 0.40–1.09), 
p = 0.10, and OR = 1.08 (95% CI 0.70–1.65), p = 0.71, 
respectively]. Paradoxically, the eﬀects of statins appeared 
statistically signiﬁcant in patients with unknown or missing 
data on ejection fraction [n = 525 (≈ 26%)], where OR = 
0.48 (95% CI 0.25–0.90), p = 0.02.
4  Discussion
Statins are not solely recommended in HF, but are still 
widely prescribed in current practice [18], and in contrast, 
observational studies have often reported mortality ben-
eﬁts [6, 19]. Our analysis from the EPICAL2 cohort failed 
to show an impact of statins on all-cause mortality in HF. 
These results are in accordance with those found in previous 
clinical trials and a meta-analysis of randomized clinical 
trials [2–4]. Patients who received statins were younger and 
more often male, obese, and subject to comorbidities (diabe-
tes, kidney disease), but had less severe HF, less often expe-
rienced arrhythmia or atrial ﬁbrillation, were more often 
treated with BBs and ACE-i, and were previously more 
exposed to statins.
Our study used propensity score matching to estimate 
treatment eﬀects. This method is believed to reduce inher-
ent biases like allocation or selection bias. We veriﬁed 
covariate balance by measuring standardized diﬀerences 
before and after matching. A balance of covariates is sat-
isﬁed if it results in a standardized diﬀerence of < 21.2% 
[20–22]. We estimated the ATT (i.e., an estimation on the 
average) because it is an interesting summary of individ-
ual causal eﬀects [23]. An instrumental variable is often 
diﬃcult to identify and has to be strongly related to the 
treatment and indirectly to the outcome. An instrument is 
potentially bad if it is correlated with omitted variables or 
the error term [24]. Our instrument “prevalence of statin 
prescription by participating hospital” appeared poten-
tially strong, and we were able to estimate the treatment 
by statins using a two-stage least square regression. The 
similar results from the instrumental variable approach 
and propensity score analyses might be of interest [25]. 
In subgroup analysis according to the type of HF (HFrEF 
and HFpEF), the eﬀects of statins on mortality outcome 
remained statistically insigniﬁcant. This result might be in 
conﬂict with the study of Nochioka et al. [5] that reported 
mortality beneﬁts in HFpEF. Nevertheless, it could be 
attributed to a smaller sample size and diﬀerent classiﬁ-
cation of patients in our study: patients with an ejection 
fraction of ≥ 50% were considered HFpEF versus ≥ 40% 
in our analysis.
We acknowledge several limitations. First, we adjusted 
for selected variables that we believe were related to both 
the treatment assignment and the outcome. Even if the 
assumption of treatment assignment ignorability is satis-
ﬁed, because of selection of observable covariates, a selec-
tion bias still potentially exists [26]. Second, we ignored 
the fact that we could have included in our models only 
those variables with signiﬁcant p values; doing so might 
have been a source of bias, as we might have failed to 
include a relevant variable that might aﬀect the outcome. 
Third, statin treatment is considered among the choles-
terol-lowering drugs, and our analysis did not include any 
cholesterol level measurement at baseline or follow-up. 
Fourth, the variables (LVEF, BMI, hospital stay dura-
tion, and hemoglobin level) used in the propensity score 
model had missing values, and the way to deal with this 
missingness involved other methods [27, 28] to be con-
sidered in further research, and this might lead to a lack 
of power in our results. Fifth, Kaplan–Meier curves did 
not have censored patients other than those who survived 
beyond 1 year of follow-up (potential performance bias). 
Those who left the study before the end or who were lost 
to follow-up at some time during the study’s 1-year follow-
up were deleted at the pre-analysis level (Fig. 1) instead 
of being censored. This was due to our primary analysis 
method that involved propensity score analyses. Moreover, 
only all-cause mortality was recorded, not the more spe-
ciﬁc HF-related mortality, with only 1-year of follow-up 
and no other relevant outcomes (e.g., rehospitalization). 
Sixth, our study did not follow patients’ drug prescrip-
tions from a family physician, for instance, after hospital 
discharge, nor the observance and real intake of statins. 
Seventh, we were not able to undergo further subgroup 
analyses [e.g., according to the type of statin (hydrophilic 
versus lipophilic)]. One potential reason was due to our 
relatively small population and the presence of missing 
data. Eighth, our data dated back to 2011/2012, which 
might be seen as relatively old. However, we noticed that 
there was little change in clinical practice concerning our 
studied question. For instance, the recommendations of 
the European Society of cardiology (ESC) regarding statin 
use in HF had not changed from the old version (2013) 
to the more recent one (2016). Thus, this is unlikely to 
impact our results from EPICAL2 data. Finally, our study 
provides evidence consistent with large-scale randomized 
clinical trials and recent systematic reviews and current 
ESC guidelines [2–4, 29], though it should be interpreted 
with caution considering the aforementioned limitations.
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5  Conclusions
Statins prescription was not associated with a decrease in 
all-cause mortality in the statin-treated group in HF patients 
(with reduced or preserved ejection fraction) after 1-year 
from hospital discharge compared with those not treated 
with statins. Within its limitations, our study adds evidence 
to the current literature, as our results are based on real-
world data.
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